Revvity stock trades near recent highs as guidance lifts revenue outlook

Revvity stock is trading close to its recent high after the company raised full-year 2026 revenue guidance and reported second quarter growth in its health science solutions business.

Revvity Inc. (US76155R1086) stock is trading close to its recent high after the company raised its full-year 2026 revenue guidance on the back of second quarter sales growth in its health science solutions portfolio, as highlighted in reporting dated August 31, 2026.

Revenue growth and higher 2026 outlook

Recent coverage of Revvity indicates that in the second quarter of 2026 the company generated revenue of $730 million from its operations, framed as a pro forma increase of 4 percent compared with the prior-year period, underscoring steady demand for its genomic analysis, diagnostics, and omics services offerings. In the same context, full-year 2026 revenue guidance was raised to a range of $2.83 billion to $2.86 billion, implying expected pro forma growth of 4 percent to 5 percent for the year and signaling management confidence in the trajectory of the business.

The step-up in revenue expectations matters for investors because it suggests that Revvity now anticipates adding between $110 million and $140 million in sales compared with a $2.72 billion level that would correspond to flat performance, and the guided pro forma growth band sets a clear numerical yardstick against which upcoming quarters will be judged. With the second quarter already showing 4 percent pro forma growth, achieving the upper end of the 5 percent full-year target would require incremental acceleration in the second half, a dynamic that investors will watch closely as new diagnostic and genomics-related contracts are signed.

Share price, 52-week high and market cap context

On August 31, 2026, a European-traded line of Revvity reflecting the company’s shares was quoted at EUR 109.85, with the same value marked as both the opening and latest price and a change of minus EUR 0.05, or minus 0.05 percent, at 8:21 a.m. Central European time, indicating that the shares were essentially flat in early trading while holding a triple-digit level. Market commentary on health science names notes that Revvity recently reached a 52-week high of $130.07 on its primary listing, providing a clear reference point for the current price and showing that the stock has pushed into the upper part of its one-year trading range.

Additional market data compiled for Revvity points to a market capitalization of $10.766 billion for the company in recent trading, paired with a price-to-earnings ratio of 18.53 that situates the stock in a mid-teens earnings multiple band compared with many life science tools and diagnostics peers that often trade at higher valuation levels. The relationship between the market capitalization and the raised revenue guidance implies that Revvity is valued at under four times the midpoint of the 2026 sales range, which can be calculated by dividing the $10.766 billion equity value by the roughly $2.845 billion midpoint of guided revenue, a ratio that provides investors with a concrete yardstick for comparing the stock’s valuation to other health science solution providers.

Short-interest data for Revvity’s stock indicates that 7.05 million shares are currently sold short, providing a measure of how much of the company’s float is being used in bearish or hedging positions. While the absolute number of shorted shares does not by itself determine the trajectory of the stock, the presence of several million shares on the short side can create the potential for faster moves should fundamentals surprise positively or guidance be lifted further, particularly given the backdrop of a stock that has recently tested 52-week high levels.

Analyst stance and institutional activity

Recent analyst consensus metrics collected for Revvity show that the stock is currently assigned an average rating of Hold, with an average published price target of $108.36. This target, set by covering analysts, sits below the reported 52-week high of $130.07 and therefore encapsulates a view that the stock is trading somewhat ahead of the consensus fair value implied by these models, even as the company raises its revenue guidance. For investors, the numerical gap between the 52-week high and the $108.36 average target, a difference of $21.71, frames how cautious or constructive the analyst community is relative to the share price action.

Institutional trading data highlighted on August 31, 2026, shows that a professional investment manager recently purchased 11,828 Revvity shares, indicating continuing interest in the name from active asset managers who follow the diagnostics and health science tools space. While a single trade of 11,828 shares is not transformative for a company with a market capitalization of $10.766 billion, it illustrates that the stock continues to attract portfolio flows at a time when short interest stands at 7.05 million shares and the consensus rating is only at Hold, suggesting that different investor groups are making varying numerical assessments of Revvity’s risk-reward profile.

Promotional offer on research reagents

Alongside its financial and market developments, Revvity is currently running a limited-time promotional campaign for customers in its research reagents and consumables segment. An offer branded as a time-sensitive discount spans the period from August 31 to September 7, 2026, giving buyers a 15 percent reduction on list prices for selected research reagents, consumables, and minor accessories when using a specified promotion code at checkout. The promotion then steps down to a 10 percent discount from September 8 to September 14 and a 5 percent discount from September 15 to September 22, creating a clear numerical incentive for laboratories and research institutions to place orders earlier in the promotional window.

This structured discount ladder is an example of how Revvity seeks to drive volume in its reagents and consumables business, which supports recurring revenue and often aligns directly with usage of downstream instruments and genomic analysis platforms. For investors, the staged 15 percent, 10 percent, and 5 percent discounts over successive one-week windows provide concrete insight into how the company is using price levers to stimulate demand, potentially smoothing revenue contributions from this product category and supporting the broader full-year guidance range of $2.83 billion to $2.86 billion.

Genomic analysis and diagnostics offerings

Revvity’s health science solutions portfolio centers on the use of artificial intelligence combined with automated technology to support genomic analyses, diagnostics, and omics services, supplemented by other tools designed to assist medical professionals. This includes platforms for high-throughput sequencing workflows, sample preparation, and data interpretation that allow laboratories to process large volumes of genomic data with greater speed and consistency. Such offerings are complemented by diagnostic assays and instruments targeted at clinical settings, where accurate and timely results can have direct impacts on patient care and treatment decisions.

By integrating AI-driven analytics into its genomic and omics services, Revvity aims to help customers identify clinically relevant patterns and biomarkers within complex datasets, a capability that can enhance both research productivity and translational applications. The financial figures reported for the second quarter of 2026, with revenue of $730 million and pro forma growth of 4 percent, suggest that demand for these interconnected products and services is contributing meaningfully to the company’s top line, supporting the raised guidance range that calls for 4 percent to 5 percent pro forma revenue growth for the year.

Stock positioning and investor view

In recent trading, Revvity stock’s proximity to the reported 52-week high of $130.07, a current price level near EUR 109.85 on a European quote, and a market capitalization of $10.766 billion underline that the company’s equity remains valued in a range where fundamentals and guidance are central to investor decisions. The raised full-year 2026 revenue guidance to $2.83 billion to $2.86 billion, based on a second quarter 2026 revenue figure of $730 million and an identified pro forma growth rate of 4 percent, provides a quantified roadmap for monitoring whether the business continues to scale at the targeted pace.

For US retail investors, the key numerical signals now include the 4 percent to 5 percent guided pro forma revenue growth band, the $108.36 average analyst price target compared with the $130.07 52-week high, the $10.766 billion market capitalization paired with a price-to-earnings ratio of 18.53, and the 7.05 million shares currently sold short. As of the latest available quotes on August 31, 2026, these metrics collectively frame how Revvity stock is positioned within the broader health science and diagnostics landscape, offering a concrete basis for tracking subsequent earnings releases, guidance updates, and product-related initiatives such as the August and September discount campaign on research reagents.

Read more

Further details on Revvity’s products, services, and corporate information can be found on the company’s own website, which provides additional materials for laboratories, clinicians, and investors who follow the health science solutions sector.

Fact box

Company: Revvity Inc.

ISIN: US76155R1086

Ticker: RVTY

Exchange: New York Stock Exchange

Market cap: $10.766 billion (as of August 31, 2026)

Sector / Industry: Health care - life science tools and diagnostics

Index membership: S&P 500